

Human CellExp™ SARS-CoV-2 Spike RBD (K417N, E484K, N501Y)

01/21

CATALOG NO:	P1645-50 50 µg
ALTERNATE NAMES:	COVID-19 Spike RBD protein (K417N, E484K, N501Y); 2019-nCoV Spike RBD protein (K417N, E484K, N501Y); SARS-CoV-2 Mutant (K417N, E484K, N501Y); SARS-CoV-2 (K417N, E484K, N501Y) mutant protein; South African (ZA) variant (501Y.V2, B.1.351)
MOL. WT.	35 kDa
ACCESSION NO:	YP_009724390.1
PURITY:	≥ 90% by SDS-PAGE
SOURCE:	Hek293
TAG:	His
AMINO ACID SEQUENCE:	The target protein SARS-CoV-2 S Protein RBD (K417N, E484K, N501Y) is expressed with His tag at the C-terminus.
FORM:	Lyophilized protein
FORMULATION:	Lyophilized from PBS, pH 7.5
RECONSTITUTION:	Reconstitute in sterile water to a concentration of 1 mg/ml.
STORAGE CONDITIONS:	Store at -20 °C or -80 °C. After reconstitution, divide into small aliquots and store at -20 °C or -80 °C. Avoid repeated freeze-thaw cycles.
DESCRIPTION:	SARS-CoV-2 Spike protein is a large type I transmembrane protein composed of S1 subunit and S2 subunit. During viral infection, the receptor-binding domain (RBD) of the S1 subunit is responsible for the recognition and binding of host receptor ACE2, while the S2 subunit mediates viral cell membrane fusion. The SARS-CoV-2-S1-RBD/ACE2 interaction mediates viral entry into the target cells. The 501Y.V2 variant or lineage B.1.351 was first detected in South Africa. The variant contains three spike receptor binding site mutations (K417N, E484K and N501Y) that have been shown to mildly increase receptor binding.




Fig A. 2 µg of SARS-CoV-2 Spike RBD (K417N, E484K, N501Y) was loaded on SDS-PAGE and visualized by Coomassie blue stain.

RELATED PRODUCTS:

Human CellExp™ SARS-CoV-2 Spike Protein (RBD), Recombinant (P1530)
 Recombinant SARS-CoV-2 NSP7 (Cat. No. P1647)
 Human CellExp™ Coronavirus Spike Protein (SARS-CoV-2; S1), Recombinant (P1524)
 Recombinant COVID-19 3C-like Proteinase (Cat. No. P1606)
 Human CellExp™ SARS-CoV-2 Spike RBD (N501Y), Recombinant (Cat. No. P1644)